PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportshyperaldosteronism
MeSH D006929 - hyperaldosteronism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000308:Adrenocortical hyperfunction
$
Success rate
D006929: 
Hyperaldosteronism
$
Success rate
D001477:Bartter syndrome
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaSpironolactone Spironolactone  1982-01-01   
Hydrochlorothiazide, Spironolactone Spironolactone W/ Hydrochlorothiazide  1982-05-24   
MylanSpironolactone Spironolactone  2001-08-20   
Hydrochlorothiazide, Spironolactone Spironolactone Hydrochlorothiazide  1982-01-01   
PfizerHydrochlorothiazide, Spironolactone Aldactazide  1982-12-30   
Spironolactone Aldactone  1982-12-30   
Hydrochlorothiazide, Spironolactone Spironolactone W/ Hydrochlorothiazide  1983-02-22   
Aurobindo PharmaSpironolactone Spironolactone  2014-03-06   
Zydus TherapeuticsSpironolactone Spironolactone  2018-07-18   
Sun Pharmaceutical IndustriesSpironolactone Spironolactone  1986-07-23   
Hydrochlorothiazide, Spironolactone Spironolactone Hydrochlorothiazide  1987-07-02   
Warner ChilcottSpironolactone Spironolactone  1982-11-18   
Amneal PharmaceuticalsSpironolactone Spironolactone  2010-07-02   
Chartwell PharmaceuticalsSpironolactone Spironolactone  1982-01-01   
Hydrochlorothiazide, Spironolactone Spironolactone Hydrochlorothiazide  1982-01-01   
Accord HealthcareSpironolactone Spironolactone  2016-09-19   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/0
Phase 2
0%
0/4
Phase 3
100%
2/2
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Pfizer
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use